Posted by Michael Wonder on 06 Dec 2022
Istesso announces FDA fast track and orphan drug designation for MBS2320
5 December 2022 - Istesso today announces that the US FDA has granted fast track designation for Istesso’s investigational metabolic reprogramming agent, MBS2320, for the treatment of patients with idiopathic pulmonary fibrosis.
MBS2320 is a first in class investigational drug which is currently in clinical development for the treatment of rheumatoid arthritis where it has demonstrated a unique profile, reducing inflammation and supporting the remodelling of damaged bone.
